Ascendis Pharma A/S

103.10 USD
-0.95 (-0.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ascendis Pharma A/S stock is up 15.47% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 CALL, 1 PUT. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Oct 14:38 17 Jan, 2025 90.00 CALL 15 20
06 Nov 14:53 15 Dec, 2023 85.00 PUT 100 284

About Ascendis Pharma A/S

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

  • Morgan Stanley
    Thu Nov 9, 08:56
  • Wedbush
    Wed Nov 8, 09:17